Lpath to Present at the 2013 JMP Healthcare Conference on July 9

Lpath to Present at the 2013 JMP Healthcare Conference on July 9 
SAN DIEGO, CA -- (Marketwired) -- 07/03/13 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive-lipid-targeted therapeutics,
today announced that it will participate in the JMP Securities
Healthcare Conference in New York, taking place July 9-10, 2013.
President and Chief Executive Officer Scott R. Pancoast will give his
presentation on Tuesday, July 9, 2013 at 2:30 p.m. EDT (11:30 a.m.
PDT). He will discuss the company's pathway to regulatory approval
and commercialization of its novel therapeutics, including its
anti-S1P antibody iSONEP(TM) which, in partnership with Pfizer, is
being studied in the Phase 2 Nexus Study as a potential treatment for
wet AMD. 
The presentation will be webcast live and available for replay for 30
days on the Lpath, Inc. corporate website under the "calendar of
events" page. To access the live webcast through the internet, log
onto the Lpath, Inc. "calendar of events" page at  
http://phx.corporate-ir.net/phoenix.zhtml?c=197881&p=irol-calendar at
least 15 minutes prior to the presentation to download and install
any necessary software. 
About Lpath
 San Diego-based Lpath, Inc. (NASDAQ: LPTN), an
antibody-platform company, is the category leader in lipidomics-based
therapeutics, an emerging field of medicine that targets bioactive
signaling lipids for treating a wide range of human disease. Lpath's
ImmuneY2(TM) drug-discovery engine has the unique ability to generate
therapeutic antibodies that bind to and inhibit bioactive lipids that
contribute to disease. The company has developed three drug
candidates, two of which -- iSONEP(TM) for wet AMD and ASONEP(TM) for
cancer -- are currently being investigated in Phase 2 trials. The
third candidate is an anti-LPA antibody that holds promise in
neuropathic pain and neurotrauma. Lpath entered into an agreement
with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive
option for a worldwide license to develop and commercialize iSONEP.
For more information, visit www.Lpath.com. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
858-926-3200
spancoast@Lpath.com 
Lpath Investor Relations
Westwicke Partners
Stefan Loren Ph.D., Managing Director
858-356-5930
sloren@westwicke.com 
 
 
Press spacebar to pause and continue. Press esc to stop.